The curative effect evaluation for Yi-Qi Yang-Yin Huo-Xue prescription in treatment of the high risk population of hepatitis B cirrhosis with chronic kidney injury

Beijing Ditan Hospital Affiliated to Capital Medical University0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Meet the Western medicine diagnosis standard of high risk population with hepatitis B cirrhosis complicated with CKD;
•2. Men or women aged 18-65;
•3. Meet the syndrome of traditional Chinese medicine belongs to Yin deficiency of liver and kidney, Qi deficiency and blood stasis.
•4. Sign the informed consent.

•1. Those who are allergy to the applied components of traditional Chinese medicine;
•2. The researchers determined that antiviral treatment should be carried out while the patients themselves did not;
•3. Cirrhosis with AKI or HRS;
•4. Patients with other hepatophilic virus infection or with autoimmune liver disease, primary biliary cirrhosis, hereditary metabolic liver disease, unrequited alcoholic liver disease and liver transplantation;
•5. Uncontrolled hypertension, diabetes, malignant tumor and other serious diseases;
•6. Previous renal calculus, chronic glomerulonephritis, nephrotic syndrome, IgA nephropathy, systemic lupus erythematosus, nephrotoxic drug-related renal damage and other kidney diseases;
•7. Baseline GFR < 60 ml / (min / 1.73 m2);
•8. Women within pregnancy and lactation period;
•9. Patients who cannot cooperate.

发起方

Beijing Ditan Hospital Affiliated to Capital Medical University